Provided by Tiger Trade Technology Pte. Ltd.

OCUMENSION-B

5.365
+0.0851.61%
Volume:500
Turnover:3K
Market Cap:4.37B
PE:-22.94
High:5.395
Open:5.395
Low:5.395
Close:5.280
52wk High:9.340
52wk Low:4.040
Shares:815.00M
HK Float Shares:815.00M
Volume Ratio:0.00
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.234
ROE:-3.45%
ROA:-1.93%
PB:1.03
PE(LYR):-22.94
PS:4.00

Loading ...

Ascletis Pharma-B Reports H1 Net Loss of RMB 320 Million, Widening by 263.5% Year-on-Year

Stock News
·
Aug 31

Ocumension Therapeutics Enrolls First Patient in Dry Eye Drug Study

MT Newswires Live
·
Aug 31

China's Angelalign H1 Revenue Rises on Higher Clear Aligner Case Volume

Reuters
·
Aug 31

Israel's BioLineRx Q2 Net Loss Widens on Higher R&D Expenses

Reuters
·
Aug 31

OCUMENSION Initiates Phase III Trial of First-in-Class Dry Eye Drug OT-202 with First Patient Enrolled in China

Bulletin Express
·
Aug 31

OCUMENSION-B's Dry Eye Candidate OT-202 Commences Late-Stage Dosing in China

Stock News
·
Aug 31

Ocumension Completes First Patient Enrollment in Phase III China Trial of Dry Eye Drug OT-202

Reuters
·
Aug 31

China's Rainmed Medical H1 Revenue Rises, Net Loss Narrows

Reuters
·
Aug 31

Hong Kong's Lee's Pharmaceutical H1 Profit Jumps on Higher-Margin Product Sales

Reuters
·
Aug 31

China's HeartCare Medical H1 Revenue Surges on Stroke Segment Growth

Reuters
·
Aug 31

Ocumension Therapeutics (SEHK:1477) Stock Growth Story Runs Into Funding Risk

Simply Wall St.
·
Aug 30

OCUMENSION-B (01477) reports 57.5M yuan adjusted net loss for the first half, narrowing by 46.74% year-on-year

Stock News
·
Aug 29

China's Ocumension Therapeutics H1 Revenue Surges on Higher Ophthalmic Product Sales

Reuters
·
Aug 28

Ocumension Redirects HK$121.87 Million of Unused IPO and Placing Proceeds to Working Capital

Bulletin Express
·
Aug 28

Ocumension Therapeutics Shifts Hk$102.5 Million IPO Proceeds to Working Capital, General Corporate Uses

Reuters
·
Aug 28

Ocumension Therapeutics FY26 H1 Net Loss Narrows 25.2% to RMB 99.02 Million; Revenue Rises 44.1% to RMB 423.7 Million

Reuters
·
Aug 28

Ocumension Therapeutics - Board Does not Recommend Distribution of an Interim Dividend

THOMSON REUTERS
·
Aug 28

Ocumension Therapeutics - Adjusted Net Loss Narrowed by 46.7% to Rmb57.5 Mln for Six Months

THOMSON REUTERS
·
Aug 28

Zhongjing Wanxi Pharma Donates One Million Yuan to Quake-Hit Gyirong in Tibet

Deep News
·
Aug 28

AI-Driven Drug Discovery Reshaping Scientific Research Paradigms, Long-Term Focus on Continuously Evolving R&D Platforms

Stock News
·
Aug 27